Search

Displaying results 911 - 920 of 10000 in total
  1. Drug

    Peginterferon beta-1a

    go.drugbank.com/drugs/DB09122
    ApprovedInvestigational

    [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men. … It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.

    Mixtures: Plegridy Pen, Plegridy PenCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Semaglutide

    go.drugbank.com/drugs/DB13928
    ApprovedInvestigational

    Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019. … [L46726] On August 15, 2025, the FDA granted Accelerated Approval for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis [L53901]

    Categories: Drugs Used in DiabetesProducts: OZEMPIC 1MG/DOSE SOLUTION FOR INJECTION IN PRE-FILLED PEN 1.34MG/ML, OZEMPIC 0.25MG, 0.5MG/DOSE SOLUTION FOR INJECTION IN PRE-FILLED PEN 1.34MG/ML
  3. Drug

    Selenic acid

    go.drugbank.com/drugs/DB11068
    Approved

    It may be found in over-the-counter daily dietary supplements as a source of [DB11135], an essential trace mineral for human health. … Selenic acid is an organic compound with the chemical formula H2SeO4.

    Mixtures: Obstetrix EC, Beta A With Vitamins C and E Plus SeleniumCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Telotristat ethyl

    go.drugbank.com/drugs/DB12095
    Approved

    [A252937] The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.[A252937] … [A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET.

  5. Drug

    Difenoxin

    go.drugbank.com/drugs/DB01501
    ApprovedIllicit

    Difenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). … It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide

  6. Drug

    Levodopa

    go.drugbank.com/drugs/DB01235
    ApprovedInvestigational

    The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. … Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after

    Mixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200
  7. Drug

    Sodium carbonate

    go.drugbank.com/drugs/DB09460
    ApprovedWithdrawn

    When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide. As a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid.

    Mixtures: ENO, ENO ORANGE
  8. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma … It is transported across the membranes including the blood-brain barrier into various tissues where it plays an essential role in the DNA synthesis, cysteine cycle and regulation of homocysteine, where

    Synonyms: N-[4-[[[(6S)-2-Amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-L-glutamic acidMixtures: Enl, Obstetrix EC
  9. Drug

    Telatinib

    go.drugbank.com/drugs/DB15393
    Investigational

    Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).

  10. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for